<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-78063" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Posterior Reversible Encephalopathy Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zelaya</surname>
            <given-names>Jaime E.</given-names>
          </name>
          <aff>UC Riverside/Riverside Community Hosp.</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Al-Khoury</surname>
            <given-names>Lama</given-names>
          </name>
          <aff>UCRSOM</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jaime Zelaya declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Lama Al-Khoury declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-78063.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Posterior reversible encephalopathy syndrome (PRES) is a neurologic disorder that can present with multiple different symptoms such as visual disturbances, seizures, headaches, and altered mentation. It is classically diagnosed based on its imaging characteristics on MRI imaging of the brain that is most commonly seen in the parieto-occipital lobes. To avoid potential pitfalls of this treatable condition, prompt recognition and diagnosis are paramount in improving patient outcomes. This activity reviews the clinical presentation, etiology, epidemiology, pathophysiology, evaluation, differential diagnosis, treatment and management, prognosis, and complications of PRES. This article also highlights the role of the interprofessional team in recognizing and treating PRES promptly to improve patient safety, quality of care, and outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Be able to better identify the symptoms and risk factors of PRES in order to implement a more prompt evaluation and treatment.</p></list-item><list-item><p>Determine the&#x000a0;potential emergent conditions that emulate PRES, and be able to outline the evaluation of such diseases to improve patient outcomes.</p></list-item><list-item><p>Be able to identify and compare the different treatment considerations for&#x000a0;those with&#x000a0;PRES.</p></list-item><list-item><p>Explain the importance of education and communication among the interprofessional team to enhance the care, safety, and outcomes of patients with PRES and be able to apply&#x000a0;effective strategies to improve care coordination among interprofessional team members to facilitate positive outcomes for patients with PRES.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=78063&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=78063">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-78063.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Posterior reversible encephalopathy syndrome (PRES) is a&#x000a0;neurological condition that has a few other common references from reversible posterior leukoencephalopathy syndrome (RPLS),&#x000a0;reversible posterior cerebral edema syndrome, posterior&#x000a0;leukoencephalopathy syndrome, hyperperfusion encephalopathy, and brain&#x000a0;capillary leak syndrome. It can&#x000a0;present with a variety of symptoms such as altered mentation or stupor, drowsiness, visual&#x000a0;disturbances (e.g., visual hallucinations, cortical blindness, hemianopia, quadrantanopia, and diplopia), seizures (focal or general tonic-clonic), and headaches.<xref ref-type="bibr" rid="article-78063.r1">[1]</xref>&#x000a0;PRES can&#x000a0;present acutely or subacutely, with symptoms developing within hours to days. Often, the presentation occurs in the context of acute uncontrolled hypertension, with systolic blood pressures ranging between 160 to 190 mmHg.<xref ref-type="bibr" rid="article-78063.r2">[2]</xref>&#x000a0;The name is designated to&#x000a0;its clinical and radiographic syndrome that is inspired by (1) radiographic findings of white matter edema (i.e., hyperintense T2 signal or hypointense T1 signal on magnetic resonance imaging (MRI)), typically found in the posterior cerebrum in a symmetric fashion (although asymmetric presentations are possible); and (2) the fact that symptoms are reversible, provided that the syndrome is recognized and treated promptly.&#x000a0;However, the name used to describe the syndrome&#x000a0;can be misleading as&#x000a0;the edema is not always localized necessarily to the posterior cerebral white matter&#x000a0;as it&#x000a0;can occur in watershed zones other than parietal-occipital regions thalamus, and sometimes in the anterior circulation.<xref ref-type="bibr" rid="article-78063.r2">[2]</xref><xref ref-type="bibr" rid="article-78063.r3">[3]</xref><xref ref-type="bibr" rid="article-78063.r4">[4]</xref>&#x000a0;Moreover, the syndrome is not always reversible. Some individuals can develop life-threatening complications, such as transforaminal cerebellar herniation and focal neurologic deficits, especially if prompt treatment is not initiated.<xref ref-type="bibr" rid="article-78063.r5">[5]</xref><xref ref-type="bibr" rid="article-78063.r3">[3]</xref></p>
      </sec>
      <sec id="article-78063.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Those at risk for developing PRES tend to have one or more of the following risk factors, triggers, or etiologies such as hypertension; preeclampsia; kidney disease (such as nephrotic syndrome, which can lead to hypovolemia and secondary hypertension via activation of the renin-angiotensin system; renal failure; liver disease; various chemotherapy agents like platinum-containing medications, gemcitabine, CHOP/R-CHOP, exposure to cytotoxic medications or immunosuppressants such as tacrolimus, sirolimus, interferon therapies as well as various immunotherapies and monoclonal antibodies like bevacizumab, pazopanib, sorafenib, and sunitinib.<xref ref-type="bibr" rid="article-78063.r3">[3]</xref><xref ref-type="bibr" rid="article-78063.r6">[6]</xref><xref ref-type="bibr" rid="article-78063.r7">[7]</xref><xref ref-type="bibr" rid="article-78063.r8">[8]</xref>&#x000a0;In addition, autoimmune disorders (such as hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, eosinophilic granulomatosis with polyangiitis, and systemic lupus erythematosus); or sepsis.<xref ref-type="bibr" rid="article-78063.r2">[2]</xref><xref ref-type="bibr" rid="article-78063.r9">[9]</xref><xref ref-type="bibr" rid="article-78063.r10">[10]</xref><xref ref-type="bibr" rid="article-78063.r11">[11]</xref><xref ref-type="bibr" rid="article-78063.r12">[12]</xref> Of these etiologies or triggers, uncontrolled hypertension is the most common.<xref ref-type="bibr" rid="article-78063.r4">[4]</xref>&#x000a0;However, having acute hypertension does not suggest that an individual will develop PRES, and it is difficult to determine which hypertensive individuals will develop PRES.<xref ref-type="bibr" rid="article-78063.r2">[2]</xref><xref ref-type="bibr" rid="article-78063.r13">[13]</xref></p>
      </sec>
      <sec id="article-78063.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>PRES is a syndrome that has been historically underdiagnosed, perhaps due to limited awareness; however, given the increasing availability of imaging, and improvement in the quality of imaging, awareness of PRES has improved, and an understanding of the epidemiology of PRES has been emerging. Based on several reports and studies, PRES affects people of all ages but&#x000a0;is more common in middle-aged females.<xref ref-type="bibr" rid="article-78063.r1">[1]</xref><xref ref-type="bibr" rid="article-78063.r14">[14]</xref></p>
        <p>In a retrospective study involving the review of demographics, risk factors, and clinical presentation of 113 patients with PRES, Fugate, and colleagues found that 51 individuals (45%) had an autoimmune disease with most of the individuals&#x000a0;presenting&#x000a0;with seizures (74%), followed by encephalopathy (28%), headache (26%), and visual disturbance (20%).<xref ref-type="bibr" rid="article-78063.r4">[4]</xref> Having an epileptic seizure at presentation was found to be the best predictor for PRES, and encephalopathy was the second-best predictor.&#x000a0;The same study found that having a recent&#x000a0;exposure to chemotherapy and those with underlying renal failure were also crucial predictors of PRES.<xref ref-type="bibr" rid="article-78063.r15">[15]</xref></p>
      </sec>
      <sec id="article-78063.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of PRES remains unclear, but some proposed mechanisms center around the dysregulation of cerebral autoregulation, the brain&#x02019;s ability to maintain constant cerebral blood flow over a range of blood pressures via the constriction or dilation of the cerebral blood vessels.<xref ref-type="bibr" rid="article-78063.r2">[2]</xref>&#x000a0;When blood pressures are high, typically above a systolic pressure of 160 mmHg for most people, the amount of vasoconstriction to achieve constant cerebral blood flow is maximized, and blood flow begins to rise with increasing blood pressure. Increased hydrostatic pressure can contribute to the breakdown of the blood-brain barrier, causing intravascular fluid to extravasate to the surrounding brain tissue, leading to edema. There is the belief that posterior circulation is mostly affected in cases of PRES because it has fewer adaptive mechanisms to regulate the extent of extravasation and the breakdown of the blood-brain barrier in the context of high blood pressure compared to anterior circulation.<xref ref-type="bibr" rid="article-78063.r16">[16]</xref>&#x000a0;Such speculation is perhaps inspired by findings of a formaldehyde histofluorescence study conducted by Edvinsson and colleagues that revealed a more significant number of adrenergic perivascular fibers innervating the anterior cerebral circulation compared to the vertebral circulation.<xref ref-type="bibr" rid="article-78063.r17">[17]</xref>&#x000a0;The amount of sympathetic nerve involvement is thought to be proportional to the effectiveness of autoregulation.<xref ref-type="bibr" rid="article-78063.r16">[16]</xref>&#x000a0;</p>
        <p>One critique of the hypertensive-hyperperfusion hypothesis above is that there have been cases where individuals exhibited PRES. Still, their blood pressures were not high enough to surpass the autoregulative capability of the brain.<xref ref-type="bibr" rid="article-78063.r1">[1]</xref><xref ref-type="bibr" rid="article-78063.r18">[18]</xref>&#x000a0;Not all cases of PRES occur in the context of hypertension. For instance, there have been some case reports that revealed the presence of PRES in normotensive individuals who have been taking cytotoxic therapies, such as tacrolimus in the context of liver transplantation, lending credence to the idea that endothelial dysfunction plays a crucial role in the pathophysiology of the disease.<xref ref-type="bibr" rid="article-78063.r1">[1]</xref><xref ref-type="bibr" rid="article-78063.r3">[3]</xref>&#x000a0;Although not yet fully understood, tacrolimus, cyclosporine, cisplatin, and other immunosuppressants can have direct toxic effects on the endothelium, compromising the blood-brain barrier.<xref ref-type="bibr" rid="article-78063.r3">[3]</xref><xref ref-type="bibr" rid="article-78063.r16">[16]</xref></p>
        <p>The theory of ischemia as a proposed mechanism from dysregulated cerebral autoregulation leading to vasoconstriction and then resultant cytotoxic edema has been considered based on some patients showing vasoconstriction in radionuclide studies.<xref ref-type="bibr" rid="article-78063.r19">[19]</xref><xref ref-type="bibr" rid="article-78063.r20">[20]</xref><xref ref-type="bibr" rid="article-78063.r21">[21]</xref><xref ref-type="bibr" rid="article-78063.r22">[22]</xref>&#x000a0;These results reflect a minority of patients, and further pathology studies have failed to show evidence of ischemia or infarction.&#x000a0;<xref ref-type="bibr" rid="article-78063.r23">[23]</xref></p>
        <p>Immunosuppressants can affect not only the blood-brain barrier but also neuroinflammation, such as in the context of sepsis and metabolic disorders like uremia, hypomagnesemia, and autoimmune disorders. Astrogliosis, microgliosis, and endothelial activation occurring in sepsis or endothelial injury in anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitides can enhance blood-brain barrier permeability, allowing for extravasation of intravascular fluid and potential for developing PRES.<xref ref-type="bibr" rid="article-78063.r12">[12]</xref><xref ref-type="bibr" rid="article-78063.r24">[24]</xref><xref ref-type="bibr" rid="article-78063.r25">[25]</xref><xref ref-type="bibr" rid="article-78063.r26">[26]</xref></p>
      </sec>
      <sec id="article-78063.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>PRES is a clinical and radiographic diagnosis&#x000a0;and performing a thorough history and physical examination is indispensable. There are multiple different clinical presentations that can vary in severity and acuity. The most common presenting symptoms include&#x000a0;headache (50%), encephalopathy (28%), visual&#x000a0;disturbances&#x000a0;like binocular diplopia, vision loss, no light perception vision, hemianopia, or quadrantanopia(39%), seizures (80%), and focal neurological deficits (10-15%).<xref ref-type="bibr" rid="article-78063.r27">[27]</xref> Sometimes the affected individual may have changes in mental status and not provide a reliable history; therefore, obtaining collateral information from relatives, friends, or acquaintances is valuable. While only a few patients will be normotensive,&#x000a0;up to 75% will have moderately to severely elevated blood pressure on initial presentation.<xref ref-type="bibr" rid="article-78063.r18">[18]</xref> Some theorize that it is not the height of the blood pressure but the rapidity of the elevation, similar to the theory with febrile seizures in children, not the height of the fever, but the rapidity of its elevation. When conducting a physical examination, attention to the following should be noted: hemianopia, quadrantanopia, visual neglect, cortical blindness, horizontal gaze palsy with intact vestibulo-ocular reflex, papilledema, oral trauma (tongue biting seen during a seizure), brisk reflexes, active convulsions, and urinary and fecal incontinence.<xref ref-type="bibr" rid="article-78063.r28">[28]</xref><xref ref-type="bibr" rid="article-78063.r29">[29]</xref></p>
      </sec>
      <sec id="article-78063.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Imaging remains essential and the gold standard in the diagnosis of PRES as it cannot be made based on clinical symptoms alone.<xref ref-type="bibr" rid="article-78063.r30">[30]</xref>&#x000a0;A head CT is critical to assess for neurologic emergencies that can explain an acute onset of altered mentation, headache, and seizures, such as intracranial hemorrhage. An MRI of the brain without intravenous (IV) contrast is the imaging modality of choice, looking for the presence of vasogenic edema that will appear as a hyperintense signal on T2 with the fluid-attenuated inversion recovery (FLAIR) sequences helping to improve sensitivity. This is most commonly seen in the parieto-occipital lobes&#x02014;although other areas can be involved, such as the temporal lobe, frontal lobe (superior frontal gyrus), cerebellum, brainstem, and deep white matter.<xref ref-type="bibr" rid="article-78063.r4">[4]</xref>&#x000a0;The cortex is theorized to be more involved&#x000a0;than white matter and is more densely packed and able to resist the accumulation of edema. The MRI will also help in the evaluation of other potential diagnoses, such as hypoxic-ischemic encephalopathy, posterior circulation infarct, and primary central nervous system vasculitis.<xref ref-type="bibr" rid="article-78063.r2">[2]</xref>&#x000a0;When the classic posterior cerebral hemispheres are involved, what differentiates it from an infarction of the posterior cerebral artery infarction, is the sparing of the calcarine and paramedian parts of the occipital lobe. Similarly, the use of diffusion-weighted imaging (DWI)&#x000a0;can aid in the differentiation of PRES from stroke and be either hypo- or isointense.</p>
        <p>Vascular imaging with either a CTA or magnetic resonance angiography (MRA) of the brain, which is typically normal in PRES, can sometimes show focal vasoconstriction or vasodilation patterns present in CNS vasculitis; and magnetic resonance venography (MRV), which is also typically normal in PRES, can help exclude sagittal sinus thrombosis as a possible diagnosis.<xref ref-type="bibr" rid="article-78063.r31">[31]</xref>&#x000a0;</p>
        <p>Part of the workup for PRES also includes the evaluation of potential etiologies since their identification will be crucial for management. Obtaining blood work can help evaluate electrolyte imbalances like uremia and hypomagnesemia, hypoalbuminemia, protein deficiency, and CSF studies for underlying infection (for example, herpes simplex virus type 1 or 2, which can cause herpes simplex encephalitis), and autoimmune etiologies. Blood work can also help exclude severe hypoglycemia as a potential diagnosis. A lumbar puncture is sometimes done in immunocompromised individuals or others with clinical suspicion of infection in order to assess for&#x000a0;the presence of encephalitis.</p>
        <p>Obtaining an electroencephalogram (EEG) in people with PRES can be helpful. For instance, if there is persistently altered mentation in the absence of tonic, clonic, or tonic-clonic movements, an individual may have subclinical seizure activity that can be captured on EEG. EEG patterns, however, are generally non-specific.<xref ref-type="bibr" rid="article-78063.r32">[32]</xref></p>
      </sec>
      <sec id="article-78063.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Identifying, treating, and managing the underlying etiology, in addition to careful treatment of hypertension, is crucial for the management of PRES. There is no specific, established antihypertensive regimen for the treatment of acute hypertension in people with PRES.<xref ref-type="bibr" rid="article-78063.r33">[33]</xref>&#x000a0;Treatment is recommended when the blood pressure exceeds 160 mmHg/110 mmHg, with a goal of 130 to 150 mmHg/80 to 100 mmHg.<xref ref-type="bibr" rid="article-78063.r29">[29]</xref>&#x000a0;A sudden or drastic reduction of blood pressure can lead to cerebral hypoperfusion and increase the risk of developing ischemia; thus, blood pressure should not be reduced by more than 25% of the initial presenting blood pressure in the first six hours.<xref ref-type="bibr" rid="article-78063.r29">[29]</xref>&#x000a0;Such careful acute blood pressure management may warrant a need for admission to the intensive care unit until a stable blood pressure goal is reached with the use of titratable IV antihypertensives like nicardipine, clevidipine, and labetalol. Thereafter, maintaining target blood pressure on the medical floors and in the outpatient setting is recommended. The exact duration for treatment post-acutely with antihypertensives is unclear and will vary among individuals.&#x000a0;</p>
        <p>Sometimes individuals with PRES develop life-threatening complications, such as status epilepticus or coma, and treatment and management of such complications at an intensive care unit (ICU) should follow.<xref ref-type="bibr" rid="article-78063.r34">[34]</xref>&#x000a0;At this time, there is no established antiepileptic treatment for seizures in people with PRES, and studies aimed to identify a specific antiseizure regimen are lacking but common medications such as levetiracetam and phenytoin are often used.<xref ref-type="bibr" rid="article-78063.r33">[33]</xref>&#x000a0;Some antiepileptic treatment is given during the acute phase of PRES and discontinued once PRES resolves.<xref ref-type="bibr" rid="article-78063.r35">[35]</xref>&#x000a0;In certain circumstances, complications such as epilepsy emerge, and treatment with antiepileptic drugs will be long-term.<xref ref-type="bibr" rid="article-78063.r1">[1]</xref></p>
        <p>Corticosteroids&#x000a0;have been theorized to improve the symptoms of PRES through their role in reducing vasogenic edema, however, this has not been shown to be the case clinically as there are no reports of their success in clinical practice and they have even been shown to be a trigger for causing PRES in some patients taking it for asthma.<xref ref-type="bibr" rid="article-78063.r36">[36]</xref>&#x000a0;&#x000a0;If PRES is attributed to an immunosuppressant like bevacizumab, pazopanib, sorafenib, and sunitinib, a reduction of the dose or substitution of the agent is recommended.<xref ref-type="bibr" rid="article-78063.r37">[37]</xref></p>
      </sec>
      <sec id="article-78063.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of PRES is broad and includes the following:<xref ref-type="bibr" rid="article-78063.r2">[2]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Intracranial hemorrhage</p>
          </list-item>
          <list-item>
            <p>Subdural hemorrhage</p>
          </list-item>
          <list-item>
            <p>Subarachnoid hemorrhage</p>
          </list-item>
          <list-item>
            <p>Cerebral sinus venous thrombosis</p>
          </list-item>
          <list-item>
            <p>Posterior circulation ischemic or hemorrhagic stroke</p>
          </list-item>
          <list-item>
            <p>Thrombosis of the basilar artery</p>
          </list-item>
          <list-item>
            <p>Encephalitis (autoimmune or infectious etiologies like HSV)</p>
          </list-item>
          <list-item>
            <p>Uremic encephalopathy</p>
          </list-item>
          <list-item>
            <p>Hypoglycemia</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-78063.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of PRES is typically favorable if recognized and treated early, with symptom improvement or resolution in a few days to several weeks.<xref ref-type="bibr" rid="article-78063.r2">[2]</xref><xref ref-type="bibr" rid="article-78063.r14">[14]</xref>&#x000a0;Visual symptoms often completely resolve, especially with early treatment of PRES, although there are some reported cases where residual visual deficits can remain (albeit improved) at 3 to 4 months after onset.<xref ref-type="bibr" rid="article-78063.r27">[27]</xref>&#x000a0;Although rare, it is unclear which individuals are at risk of having prolonged visual deficits and/or persistent seizures. PRES symptom irreversibility can ensue if treatment is delayed. If the amount of cerebral vasogenic edema is large, the prognosis can worsen, as the increased pressure&#x000a0;to the surrounding blood vessels can compromise blood flow and result in ischemia.<xref ref-type="bibr" rid="article-78063.r16">[16]</xref>&#x000a0;In certain situations, if there is the involvement of the brainstem, the prognosis can also worsen.<xref ref-type="bibr" rid="article-78063.r16">[16]</xref>&#x000a0;Recurrence of PRES is possible and has been reported in individuals undergoing dialysis.<xref ref-type="bibr" rid="article-78063.r2">[2]</xref></p>
      </sec>
      <sec id="article-78063.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of PRES can develop if the disease is not treated promptly. Complications include focal neurologic deficits from ischemic injury, epilepsy, and life-threatening conditions, such as transforaminal cerebellar herniation, which is reported&#x000a0;as one of the most common neurological complications that occur in children following hematopoietic stem cell transplantation.<xref ref-type="bibr" rid="article-78063.r5">[5]</xref><xref ref-type="bibr" rid="article-78063.r38">[38]</xref><xref ref-type="bibr" rid="article-78063.r5">[5]</xref></p>
      </sec>
      <sec id="article-78063.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Early recognition and treatment of PRES can help reduce the incidence of complications and improve patient outcomes. Awareness and education are instrumental for the proper management of PRES and its risk factors and etiologies. For instance, educating patients about blood pressure management can decrease the likelihood of cerebral autoregulation dysfunction, leading to PRES and other complications. Knowledge about the effects of cytotoxic immunosuppressants on the blood-brain barrier, even in non-hypertensive patients, can help care providers become more mindful of the development of PRES in patients taking these medicines.</p>
      </sec>
      <sec id="article-78063.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Enhancement of healthcare team outcomes for PRES rests on education and effective communication among physicians, nurses, technicians, therapists, and every member involved in patient care, especially patients themselves. This teamwork is key given the variety of different presenting symptoms this condition can have along with the needed imaging modalities required for an accurate diagnosis. As mentioned, a CT scan of the brain is not sufficient to rule out this diagnosis and is most commonly diagnosed on MRI imaging of the brain. The involvement of the radiologist is important given key imaging findings. Effective communication, awareness, and recognition of PRES can improve&#x000a0;a more prompt diagnosis and resultant improved treatment thus preventing lethal complications. Enhancing collaboration between the neurological and critical care services is essential given the needed control of a patient's blood pressure&#x000a0;using titratable drips that require&#x000a0;both nursing staff and pharmacy practitioners.&#x000a0;Collaboration, shared decision-making, and communication between these healthcare teams are&#x000a0;key&#x000a0;elements for a good neurological outcome. The interprofessional care provided to the patient must use an integrated care pathway combined with an evidence-based approach to planning and evaluation of all joint activities.</p>
      </sec>
      <sec id="article-78063.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=78063&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=78063">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/neurology/posterior-reversible-encephalopathy-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=78063">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/78063/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=78063">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-78063.s15">
        <title>References</title>
        <ref id="article-78063.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fischer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schmutzhard</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Posterior reversible encephalopathy syndrome.</article-title>
            <source>J Neurol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>264</volume>
            <issue>8</issue>
            <fpage>1608</fpage>
            <page-range>1608-1616</page-range>
            <pub-id pub-id-type="pmid">28054130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hobson</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Craven</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Blank</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Posterior reversible encephalopathy syndrome: a truly treatable neurologic illness.</article-title>
            <source>Perit Dial Int</source>
            <year>2012</year>
            <season>Nov-Dec</season>
            <volume>32</volume>
            <issue>6</issue>
            <fpage>590</fpage>
            <page-range>590-4</page-range>
            <pub-id pub-id-type="pmid">23212858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hinchey</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chaves</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Appignani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Breen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pessin</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Lamy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mas</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Caplan</surname>
                <given-names>LR</given-names>
              </name>
            </person-group>
            <article-title>A reversible posterior leukoencephalopathy syndrome.</article-title>
            <source>N Engl J Med</source>
            <year>1996</year>
            <month>Feb</month>
            <day>22</day>
            <volume>334</volume>
            <issue>8</issue>
            <fpage>494</fpage>
            <page-range>494-500</page-range>
            <pub-id pub-id-type="pmid">8559202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fugate</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Claassen</surname>
                <given-names>DO</given-names>
              </name>
              <name>
                <surname>Cloft</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Kallmes</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Kozak</surname>
                <given-names>OS</given-names>
              </name>
              <name>
                <surname>Rabinstein</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2010</year>
            <month>May</month>
            <volume>85</volume>
            <issue>5</issue>
            <fpage>427</fpage>
            <page-range>427-32</page-range>
            <pub-id pub-id-type="pmid">20435835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cordelli</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Masetti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ricci</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Toni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zama</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Maffei</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gentili</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Parmeggiani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pession</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Franzoni</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Life-threatening complications of posterior reversible encephalopathy syndrome in children.</article-title>
            <source>Eur J Paediatr Neurol</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>18</volume>
            <issue>5</issue>
            <fpage>632</fpage>
            <page-range>632-40</page-range>
            <pub-id pub-id-type="pmid">24814477</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ito</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Arahata</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Goto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hirayama</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nagamutsu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yasuda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yanagi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sobue</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome.</article-title>
            <source>AJNR Am J Neuroradiol</source>
            <year>1998</year>
            <month>Mar</month>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>415</fpage>
            <page-range>415-7</page-range>
            <pub-id pub-id-type="pmid">9541291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozcan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Hari</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Reversible posterior leukoencephalopathy syndrome and bevacizumab.</article-title>
            <source>N Engl J Med</source>
            <year>2006</year>
            <month>Mar</month>
            <day>02</day>
            <volume>354</volume>
            <issue>9</issue>
            <fpage>980</fpage>
            <page-range>980-2; discussion 980-2</page-range>
            <pub-id pub-id-type="pmid">16514715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allen</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Adlakha</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bergethon</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.</article-title>
            <source>Arch Neurol</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>63</volume>
            <issue>10</issue>
            <fpage>1475</fpage>
            <page-range>1475-8</page-range>
            <pub-id pub-id-type="pmid">17030665</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bodkin</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Eidelman</surname>
                <given-names>BH</given-names>
              </name>
            </person-group>
            <article-title>Sirolimus-induced posterior reversible encephalopathy.</article-title>
            <source>Neurology</source>
            <year>2007</year>
            <month>Jun</month>
            <day>05</day>
            <volume>68</volume>
            <issue>23</issue>
            <fpage>2039</fpage>
            <page-range>2039-40</page-range>
            <pub-id pub-id-type="pmid">17548556</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rajasekhar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature.</article-title>
            <source>Oncologist</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>12</volume>
            <issue>11</issue>
            <fpage>1332</fpage>
            <page-range>1332-5</page-range>
            <pub-id pub-id-type="pmid">18055853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Junna</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Rabinstein</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Tacrolimus induced leukoencephalopathy presenting with status epilepticus and prolonged coma.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>78</volume>
            <issue>12</issue>
            <fpage>1410</fpage>
            <page-range>1410-1</page-range>
            <pub-id pub-id-type="pmid">18024699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garner</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ramirez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Iardino</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A case of posterior reversible encephalopathy syndrome associated with sepsis.</article-title>
            <source>BMJ Case Rep</source>
            <year>2018</year>
            <month>Jul</month>
            <day>10</day>
            <volume>2018</volume>
            <pub-id pub-id-type="pmid">29991547</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chowdhary</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kabbani</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Tobey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hope</surname>
                <given-names>TD</given-names>
              </name>
            </person-group>
            <article-title>Posterior reversible encephalopathy syndrome in a woman with focal segmental glomerulosclerosis.</article-title>
            <source>Neuropsychiatr Dis Treat</source>
            <year>2015</year>
            <volume>11</volume>
            <fpage>1111</fpage>
            <page-range>1111-4</page-range>
            <pub-id pub-id-type="pmid">25960654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sundin</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Posterior Reversible Encephalopathy Syndrome.</article-title>
            <source>MCN Am J Matern Child Nurs</source>
            <year>2018</year>
            <season>Mar/Apr</season>
            <volume>43</volume>
            <issue>2</issue>
            <fpage>77</fpage>
            <page-range>77-82</page-range>
            <pub-id pub-id-type="pmid">29470266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Faille</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Fieuws</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Van Paesschen</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Clinical predictors and differential diagnosis of posterior reversible encephalopathy syndrome.</article-title>
            <source>Acta Neurol Belg</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>117</volume>
            <issue>2</issue>
            <fpage>469</fpage>
            <page-range>469-475</page-range>
            <pub-id pub-id-type="pmid">28144796</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Covarrubias</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Luetmer</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Campeau</surname>
                <given-names>NG</given-names>
              </name>
            </person-group>
            <article-title>Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images.</article-title>
            <source>AJNR Am J Neuroradiol</source>
            <year>2002</year>
            <season>Jun-Jul</season>
            <volume>23</volume>
            <issue>6</issue>
            <fpage>1038</fpage>
            <page-range>1038-48</page-range>
            <pub-id pub-id-type="pmid">12063238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edvinsson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Owman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sj&#x000f6;berg</surname>
                <given-names>NO</given-names>
              </name>
            </person-group>
            <article-title>Autonomic nerves, mast cells, and amine receptors in human brain vessels. A histochemical and pharmacological study.</article-title>
            <source>Brain Res</source>
            <year>1976</year>
            <month>Oct</month>
            <day>22</day>
            <volume>115</volume>
            <issue>3</issue>
            <fpage>377</fpage>
            <page-range>377-93</page-range>
            <pub-id pub-id-type="pmid">184880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bartynski</surname>
                <given-names>WS</given-names>
              </name>
            </person-group>
            <article-title>Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features.</article-title>
            <source>AJNR Am J Neuroradiol</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>29</volume>
            <issue>6</issue>
            <fpage>1036</fpage>
            <page-range>1036-42</page-range>
            <pub-id pub-id-type="pmid">18356474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ay</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Buonanno</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Koroshetz</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI.</article-title>
            <source>Neurology</source>
            <year>1998</year>
            <month>Nov</month>
            <volume>51</volume>
            <issue>5</issue>
            <fpage>1369</fpage>
            <page-range>1369-76</page-range>
            <pub-id pub-id-type="pmid">9818862</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mukherjee</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>McKinstry</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Reversible posterior leukoencephalopathy syndrome: evaluation with diffusion-tensor MR imaging.</article-title>
            <source>Radiology</source>
            <year>2001</year>
            <month>Jun</month>
            <volume>219</volume>
            <issue>3</issue>
            <fpage>756</fpage>
            <page-range>756-65</page-range>
            <pub-id pub-id-type="pmid">11376265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naidu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Moodley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Corr</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Single photon emission and cerebral computerised tomographic scan and transcranial Doppler sonographic findings in eclampsia.</article-title>
            <source>Br J Obstet Gynaecol</source>
            <year>1997</year>
            <month>Oct</month>
            <volume>104</volume>
            <issue>10</issue>
            <fpage>1165</fpage>
            <page-range>1165-72</page-range>
            <pub-id pub-id-type="pmid">9332995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tajima</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Isonishi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kashiwaba</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tashiro</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Two similar cases of encephalopathy, possibly a reversible posterior leukoencephalopathy syndrome: serial findings of magnetic resonance imaging, SPECT and angiography.</article-title>
            <source>Intern Med</source>
            <year>1999</year>
            <month>Jan</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>54</fpage>
            <page-range>54-8</page-range>
            <pub-id pub-id-type="pmid">10052744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lanzino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cloft</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hemstreet</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>West</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Alston</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ishitani</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Reversible posterior leukoencephalopathy following organ transplantation. Description of two cases.</article-title>
            <source>Clin Neurol Neurosurg</source>
            <year>1997</year>
            <month>Aug</month>
            <volume>99</volume>
            <issue>3</issue>
            <fpage>222</fpage>
            <page-range>222-6</page-range>
            <pub-id pub-id-type="pmid">9350407</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nwafor</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Brichacek</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Mohammad</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Griffith</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lucke-Wold</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Benkovic</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Geldenhuys</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Lockman</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Targeting the Blood-Brain Barrier to Prevent Sepsis-Associated Cognitive Impairment.</article-title>
            <source>J Cent Nerv Syst Dis</source>
            <year>2019</year>
            <volume>11</volume>
            <fpage>1179573519840652</fpage>
            <pub-id pub-id-type="pmid">31007531</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marra</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Barilaro</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Villella</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Granata</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Eosinophilic granulomatosis with polyangiitis (EGPA) and PRES: a case-based review of literature in ANCA-associated vasculitides.</article-title>
            <source>Rheumatol Int</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>35</volume>
            <issue>9</issue>
            <fpage>1591</fpage>
            <page-range>1591-5</page-range>
            <pub-id pub-id-type="pmid">25836767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dinsdale</surname>
                <given-names>HB</given-names>
              </name>
            </person-group>
            <article-title>Hypertensive encephalopathy.</article-title>
            <source>Neurol Clin</source>
            <year>1983</year>
            <month>Feb</month>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-16</page-range>
            <pub-id pub-id-type="pmid">6687306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lifson</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pasquale</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Salloum</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Alpert</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Ophthalmic Manifestations of Posterior Reversible Encephalopathy Syndrome.</article-title>
            <source>Neuroophthalmology</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>180</fpage>
            <page-range>180-184</page-range>
            <pub-id pub-id-type="pmid">31312242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hawatmeh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Studyvin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Al-Halawani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Amireh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thawabi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Posterior reversible encephalopathy syndrome associated with left horizontal gaze palsy.</article-title>
            <source>Ann Transl Med</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>104</fpage>
            <pub-id pub-id-type="pmid">28361069</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vandenbossche</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Maquet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vroonen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lambert</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nisolle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kridelka</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Emonts</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>A reversible posterior leucoencephalopathy syndrome including blindness caused by preeclampsia.</article-title>
            <source>Facts Views Vis Obgyn</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>173</fpage>
            <page-range>173-177</page-range>
            <pub-id pub-id-type="pmid">28003872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zou</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>SF</given-names>
              </name>
            </person-group>
            <article-title>Establishment and utility assessment of posterior reversible encephalopathy syndrome early warning scoring (PEWS) scale establishment and utility assessment of PEWS scale.</article-title>
            <source>BMC Neurol</source>
            <year>2019</year>
            <month>Feb</month>
            <day>21</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <pub-id pub-id-type="pmid">30791893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bartynski</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Boardman</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Catheter angiography, MR angiography, and MR perfusion in posterior reversible encephalopathy syndrome.</article-title>
            <source>AJNR Am J Neuroradiol</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>447</fpage>
            <page-range>447-55</page-range>
            <pub-id pub-id-type="pmid">18079186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murray</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Maciver</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Benbadis</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>EEG Findings in Posterior Reversible Encephalopathy Syndrome.</article-title>
            <source>Clin EEG Neurosci</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>50</volume>
            <issue>5</issue>
            <fpage>366</fpage>
            <page-range>366-369</page-range>
            <pub-id pub-id-type="pmid">31215229</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strother</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>NE</given-names>
              </name>
            </person-group>
            <article-title>Posterior Reversible Encephalopathy Syndrome Secondary to Hypertensive Encephalopathy Brought on by a MAO Inhibitor: A Case Report.</article-title>
            <source>J Prim Care Community Health</source>
            <year>2019</year>
            <season>Jan-Dec</season>
            <volume>10</volume>
            <fpage>2150132719869539</fpage>
            <pub-id pub-id-type="pmid">31423884</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gokhale</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kimona</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kantor</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prakash</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Manhas</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Posterior Reversible Leukoencephalopathy Syndrome (PRES) in Intensive Care Unit - Case series.</article-title>
            <source>Indian J Crit Care Med</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>21</volume>
            <issue>11</issue>
            <fpage>772</fpage>
            <page-range>772-778</page-range>
            <pub-id pub-id-type="pmid">29279639</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spencer</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>PRES-ing for Answers About Long-Term Seizure Risk in Patients With Posterior Reversible Encephalopathy Syndrome.</article-title>
            <source>Epilepsy Curr</source>
            <year>2015</year>
            <season>Nov-Dec</season>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>317</fpage>
            <page-range>317-8</page-range>
            <pub-id pub-id-type="pmid">26633947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roth</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ferbert</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The posterior reversible encephalopathy syndrome: what's certain, what's new?</article-title>
            <source>Pract Neurol</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>136</fpage>
            <page-range>136-44</page-range>
            <pub-id pub-id-type="pmid">21551107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gijtenbeek</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>van den Bent</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Vecht</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Cyclosporine neurotoxicity: a review.</article-title>
            <source>J Neurol</source>
            <year>1999</year>
            <month>May</month>
            <volume>246</volume>
            <issue>5</issue>
            <fpage>339</fpage>
            <page-range>339-46</page-range>
            <pub-id pub-id-type="pmid">10399863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-78063.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>At&#x000e7;a</surname>
                <given-names>A&#x000d6;</given-names>
              </name>
              <name>
                <surname>Erok</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aydo&#x0011f;du</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Neuroimaging findings of posterior reversible encephalopathy syndrome (PRES) following haematopoietic stem cell transplantation in paediatric recipients.</article-title>
            <source>BMC Pediatr</source>
            <year>2021</year>
            <month>Oct</month>
            <day>11</day>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>445</fpage>
            <pub-id pub-id-type="pmid">34629063</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
